RESEARCH TRIANGLE PARK, N.C.-January 27th 2009 - Quintiles Transnational Corp. today announced a partnership with Apollo Hospitals Group to open a Phase I clinical trial unit in Hyderabad, India. This unit will allow customers additional options to complete integrated Phase I programs across multiple geographies at this pivotal stage in medical research.
"Phase I development in both healthy volunteers and patients is at the forefront of our quest for new and better medicines. Phase I can help expedite the development process and ensure that only those compounds with most promise are further evaluated. We are expanding our global capacity in the light of increased customer demand for these services" explained Eddie Caffrey, Senior Vice President, Global Phase I.
Scheduled to open in the first quarter of 2010, the new unit will evaluate compounds developed both in India and in other countries. Initially, it will have approximately 50 beds, with plans to expand this number to 100 to meet predicted growth in demand. Hyderabad will be the fifth Quintiles Phase I facility, joining units in London, Kansas, Lulea and Uppsala.
Eddie Caffrey, Senior Vice President, Global Phase I further explains: "This new Phase I unit will draw on the existing experience of Quintiles staff in India, including our established cardiology group; the expertise of local clinicians and scientists and Quintiles' global experience in Phase I, to deliver studies in accordance with global standards and within the recently revised regulatory framework in India."
"Our partner, Apollo Hospitals Group, has an outstanding reputation and demonstrated track record for quality health care provision in India."
Dr. Prathap C. Reddy, Chairman, The Apollo Group of Hospitals says: "We are excited to be working with Quintiles on the development of this new unit. Apollo has pioneered the provision of many medical and surgical procedures in India and our mission is to bring healthcare of international standards to within the reach of every individual. We are proud to be involved in further establishing India as a center of excellence for all Phases of clinical research and once open the facility will, I believe, reinforce India in its position at the forefront of new drug development."
Senior managers from Quintiles' Phase I unit at Guy's Hospital, London, unit will set up operations in Hyderabad and mentor the management team there. Quintiles' London personnel also will help train staff for the India unit, which will be located in a building on Apollo's Hyderabad hospital campus.
Hyderabad is the fifth Quintiles location in India. The company has offices in Mumbai, Ahmadabad, Bangalore and Delhi offering extensive clinical research, central laboratory, data management and ECG services.
The combined investment is anticipated to be approximately $6 million.
About Apollo
Apollo is the largest private hospital company in India, with 41 hospitals and a total of more than 8,000 beds. Founded in 1979, the company also operates nursing and hospital management colleges, pharmacies and diagnostic clinics. Apollo was first to perform liver and multi-organ transplants in India. http://www.apollohospdelhi.com/
About Quintiles
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With more than 21,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at www.quintiles.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.